ARHGEF5

ARHGEF5 is a Dbl-family Rho guanine nucleotide exchange factor that preferentially catalyzes nucleotide exchange on RhoA and RhoB, with weak activity toward RhoC and RhoG, and is held in an auto-inhibited state by an intramolecular interaction between its C-terminal SH3 domain and an internal polyproline motif that stabilizes an inhibitory helix N-terminal to the DH domain (PMID:25645980, PMID:19713215). Relief of auto-inhibition occurs through Src-mediated tyrosine phosphorylation and Gβγ binding, enabling ARHGEF5 to drive Src-induced podosome formation via a ternary complex with Src and PI3K, and to support MIP1α-directed chemotaxis of immature dendritic cells as demonstrated by selective loss of this migration in Arhgef5-knockout mice (PMID:21525037, PMID:19713215). ARHGEF5 is upregulated during TGF-β-induced epithelial–mesenchymal transition and promotes tumor cell invasion and metastasis through the Rho-ROCK and PI3K-Akt pathways, with mesenchymal-like cancer cells becoming selectively dependent on ARHGEF5 for Akt activation and tumor growth (PMID:27617642).

1. 2009 High

   Defining substrate specificity and in vivo function: ARHGEF5 was shown to be a RhoA/RhoB-selective GEF stimulated by Gβγ subunits, and Arhgef5-null mice revealed a non-redundant requirement for immature dendritic cell chemotaxis and skin-to-lymph-node migration, establishing a specific physiological role for this exchange factor.

   Evidence In vitro GEF assays with panel of Rho GTPases, Gβγ co-immunoprecipitation, and Arhgef5-knockout mouse DC chemotaxis and migration assays

   PMID:19713215

   Open questions at the time

   • Mechanism by which Gβγ relieves auto-inhibition is not structurally resolved
   • Whether ARHGEF5 functions in mature DC or other leukocyte migration under different stimuli is untested
   • No crystal structure of the ARHGEF5-RhoA catalytic complex
2. 2011 High

   Linking ARHGEF5 to Src signaling and podosomes: ARHGEF5 was identified as a Src SH3-domain partner that is tyrosine-phosphorylated by Src, positively regulates Src activity, and is required for Src-induced podosome formation through its PH domain and a ternary complex with Src and PI3K.

   Evidence Src SH3 pulldown, RNAi knockdown with podosome quantification, tyrosine phosphorylation assays, domain deletion/mutation analysis

   PMID:21525037

   Open questions at the time

   • Identity of the specific tyrosine residue(s) phosphorylated by Src is not mapped
   • How positive feedback between ARHGEF5 and Src kinase activity is regulated to avoid runaway signaling is unclear
   • Relative contributions of RhoA versus Cdc42 activation downstream of ARHGEF5 in podosome assembly are not dissected
3. 2015 Medium

   Elucidating the auto-inhibitory mechanism: an intramolecular SH3–polyproline interaction was shown to stabilize an inhibitory helix N-terminal to the DH domain, and competitive disruption of this interaction by designed peptide aptamers activated RhoA exchange in vitro, providing a molecular basis for regulation of ARHGEF5 catalytic activity.

   Evidence Molecular dynamics simulation, in vitro GEF assay with peptide aptamers, site-directed mutagenesis of peptide residues

   PMID:25645980

   Open questions at the time

   • No experimental structure (crystal or cryo-EM) of the auto-inhibited full-length protein
   • Whether Src phosphorylation or Gβγ binding directly disrupts the SH3–polyproline interaction in cells is not demonstrated
   • In vivo validation of the peptide-aptamer activation approach is lacking
4. 2016 Medium

   Establishing a pro-metastatic role in EMT: ARHGEF5 was found to be upregulated during TGF-β-induced EMT and to be required for invasion and in vivo metastasis of colorectal cancer cells, operating through Rho-ROCK and PI3K-Akt signaling axes with mesenchymal-state selectivity.

   Evidence siRNA knockdown and overexpression in MCF10A and HCT116 cells, in vitro invasion assays, in vivo xenograft/metastasis models, EMT induction with TGF-β/TNF-α/Slug

   PMID:27617642

   Open questions at the time

   • Transcriptional mechanism of ARHGEF5 upregulation during EMT is not defined
   • Whether ARHGEF5 dependence generalizes beyond HCT116 and MCF10A models is untested
   • Direct versus indirect activation of PI3K-Akt by ARHGEF5 in mesenchymal cells is unresolved

• A full structural understanding of how Src phosphorylation, Gβγ binding, and the intramolecular SH3–polyproline switch converge to control ARHGEF5 activation remains unresolved, and additional in vivo roles beyond DC chemotaxis and cancer metastasis have not been explored.
• No high-resolution structure of full-length ARHGEF5 in auto-inhibited or active states
• Phosphosite-specific resolution of Src-mediated activation is missing
• Potential roles in other Gβγ-coupled immune or developmental processes are unexplored